Posted: Mon Jun 26, 2006 4:42 pm
Dignan
This news is music to my ears. I'm so glad they've done some research in addition to the "auto-immune" anti-inflammatory properties of estrogen and that it sounds promising.
The fact that they used a ligand suggests to me that if something eventually comes of this, it should be suitable for men as well.
I think I posted this before but it may be worth repeating. Development of 17 alpha estradiol as a neuroprotective therapeutic agent
Thanks Dignan
Sharon
This news is music to my ears. I'm so glad they've done some research in addition to the "auto-immune" anti-inflammatory properties of estrogen and that it sounds promising.
Treatment with either estradiol or the ERalpha ligand significantly reduced this gray matter pathology.
The fact that they used a ligand suggests to me that if something eventually comes of this, it should be suitable for men as well.
I think I posted this before but it may be worth repeating. Development of 17 alpha estradiol as a neuroprotective therapeutic agent
Maybe they should add MS to the list of diseases with potential therapeutic benefit.Despite its meager hormonal activity, 17alpha-E2 is as potent as 17beta-E2 in protecting a wide variety of cell types, including primary neurons, from a diverse array of lethal and etiologically relevant stressors, including amyloid toxicity, serum withdrawal, oxidative stress, excitotoxicity, and mitochondrial inhibition, among others.
Thus, by serving as a mitoprotectant, 17alpha-E2 forestalls cell death and could correspondingly provide therapeutic benefit in a host of degenerative diseases, including AD, PD, Friedreich's ataxia, and amyotrophic lateral sclerosis, while at the same time circumventing the common adverse effects elicited by more hormonally active analogues.
Thanks Dignan
Sharon